Clinical Trial Update: Oral Rigosertib for Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating oral rigosertib for various squamous cell carcinomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Squamous Cell Carcinoma
• Cervical Squamous Cell Carcinoma
• Esophageal Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Lung Squamous Cell Carcinoma
• Penile Squamous Cell Carcinoma
• Skin Squamous Cell Carcinoma

Drugs mentioned

• Rigosertib (rigosertib)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Head and Neck Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED